Arjo AB (publ) (STO:ARJO.B)
27.52
-0.08 (-0.29%)
Aug 12, 2026, 9:09 AM CET
Arjo AB Revenue
Arjo AB had revenue of 2.76B SEK in the quarter ending June 30, 2026, with 3.02% growth. This brings the company's revenue in the last twelve months to 10.92B, down -3.08% year-over-year. In the year 2025, Arjo AB had annual revenue of 11.00B, down -2.59%.
Revenue (ttm)
10.92B
Revenue Growth
-3.08%
P/S Ratio
0.69
Revenue / Employee
1.56M
Employees
7,000
Market Cap
7.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.00B | -292.00M | -2.59% |
| Dec 31, 2024 | 11.29B | 312.00M | 2.84% |
| Dec 31, 2023 | 10.98B | 1.00B | 10.03% |
| Dec 31, 2022 | 9.98B | 909.00M | 10.02% |
| Dec 31, 2021 | 9.07B | -8.00M | -0.09% |
| Dec 31, 2020 | 9.08B | 102.00M | 1.14% |
| Dec 31, 2019 | 8.98B | 759.00M | 9.24% |
| Dec 31, 2018 | 8.22B | 529.00M | 6.88% |
| Dec 31, 2017 | 7.69B | -120.00M | -1.54% |
| Dec 31, 2016 | 7.81B | -307.00M | -3.78% |
| Dec 31, 2015 | 8.12B | 547.00M | 7.23% |
| Dec 31, 2014 | 7.57B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.24B |
| Swedish Orphan Biovitrum AB | 30.62B |
| Medicover AB | 27.33B |
| Apotea AB | 7.59B |
| Synsam AB | 7.13B |
| Sectra AB | 3.65B |
| Dynavox Group AB | 2.54B |
| MedCap AB | 2.26B |
Arjo AB News
- 4 weeks ago - Arjo AB Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Arjo AB Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Arjo AB Slides: Q2 2026 - Filings
- 4 weeks ago - Arjo Earnings Up In Q2; Maintains FY26 Sales Growth Outlook - Nasdaq
- 4 months ago - Arjo AB Earnings Call Transcript: Q1 2026 - Transcripts
- 4 months ago - Arjo AB Quarterly report: Q1 2026 - Filings
- 4 months ago - Arjo AB Slides: Q1 2026 - Filings
- 6 months ago - Arjo AB Earnings Call Transcript: Q4 2025 - Transcripts